Skip to main content
OpenTrials
Completed

NCT Number: NCT00737568

Tenofovir Disoproxil Fumarate (Tenofovir DF) Versus Emtricitabine/Tenofovir DF in Subjects Resistant to Lamivudine

The aim of therapy for the treatment of chronic hepatitis B virus (HBV) is to maintain suppression of viral replication to prevent the emergence of complications, which requires long-term therapy. Durable suppression of viral replication is achieved in the treatment of chronic viral diseases by preventing of the emergence of drug-resistant mutations. The clinical guidelines for the management of lamivudine resistant patients are variable. Some recommend switching to another agent without cross-resistance, while others recommend adding on another agent without cross-resistance. Limited clinical data exists to demonstrate whether tenofovir disoproxil fumarate (tenofovir DF; TDF) is an effective monotherapy for lamivudine resistant patients or if it should be used as part of a combination therapy regimen.

This study is designed to evaluate the effectiveness, safety, and tolerability of tenofovir DF monotherapy versus emtricitabine (FTC)/tenofovir DF combination therapy in participants with chronic HBV with lamivudine resistance (presence of the rtM204I/V mutation with or without the rtL180M mutation) over a 240-week period. Participants in this study must be receiving lamivudine treatment at the time of enrollment.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hepatitis B Blood-Borne Infections Chronic Disease Communicable Diseases DNA Virus Infections Digestive System Diseases Disease Attributes Hepadnaviridae Infections Hepatitis Hepatitis B, Chronic Hepatitis, Chronic Hepatitis, Viral, Human Infections Liver Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms Virus Diseases

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Innsbruck, Austria

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Chronic HBV infection, defined as positive serum HBsAg for at least 6 months
  • 18 through 75 years of age, inclusive
  • HBV DNA ≥ 10^3 IU/mL
  • Receiving treatment with lamivudine with confirmation of HBV reverse transcriptase mutation(s) known to confer resistance to lamivudine (rtM204I/V with or without rtL180M) by central laboratory assessment prior to randomization; adefovir dipivoxil treatment of ≤ 48 weeks at the time of screening (inclusive of combination adefovir dipivoxil + lamivudine at entry) was allowed
  • Willing and able to provide written informed consent
  • Negative serum pregnancy test (for females of childbearing potential only)
  • Calculated creatinine clearance ≥ 50 mL/min
  • Hemoglobin ≥ 10 g/dL
  • Neutrophils ≥ 1000 /mm^3
  • No prior oral HBV therapy with approved nucleotide and/or nucleoside therapy or other investigational agents for HBV infection other than lamivudine or adefovir dipivoxil

Exclusion criteria

  • Pregnant women, women who are breast feeding or who believe they may wish to become pregnant during the course of the study
  • Males and females of reproductive potential who are not willing to use an effective method of contraception during the study
  • Alanine aminotransferase (ALT) ≥ 10 × the upper limit of the normal range (ULN)
  • Decompensated liver disease
  • Interferon or pegylated interferon therapy within 6 months of the screening visit
  • Alpha fetoprotein > 50 ng/mL
  • Evidence of hepatocellular carcinoma
  • Coinfection with hepatitis C virus, HIV, or hepatitis D virus
  • Significant renal, cardiovascular, pulmonary, or neurological disease
  • Received solid organ or bone marrow transplantation
  • Receiving therapy with immunomodulators (eg, corticosteroids, etc.), investigational agents, nephrotoxic agents, or agents susceptible of modifying renal excretion
  • Proximal tubulopathy
  • Known hypersensitivity to the study drugs, the metabolites or formulation excipients

Treatment and study plan

TDF

Drug

Tenofovir disoproxil fumarate (tenofovir DF; TDF) 300 mg tablet administered orally once daily

Other names: Viread®

FTC/TDF

Drug

Emtricitabine (FTC)/TDF 200/300 mg fixed-dose combination tablet administered orally once daily

Other names: Truvada®

TDF placebo

Drug

TDF placebo tablet administered orally once daily

FTC/TDF Placebo

Drug

FTC/TDF placebo tablet administered orally once daily

Primary outcomes

  1. Percentage of Participants With HBV DNA < 400 Copies/mL at Week 96

    Time frame: Week 96

Secondary outcomes

  1. Percentage of Participants With HBV DNA < 400 Copies/mL at Weeks 48, 144, 192, and 240

    Time frame: Weeks 48, 144, 192, and 240

  2. Percentage of Participants With HBV DNA < 169 Copies/mL at Weeks 48, 96, 144, 192, and 240

    Time frame: Weeks 48, 96, 144, 192, and 240

  3. HBV DNA Level at Weeks 48, 96, 144, 192, and 240

    Time frame: Weeks 48, 96, 144, 192, and 240

  4. Percentage of Participants With Normal ALT at Weeks 48, 96, 144, 192, and 240

    Time frame: Weeks 48, 96, 144, 192, and 240

    Normal ALT was defined as having a value less than or equal to the ULN. The ULN was 43 U/L for males and 34 U/L for females aged 18 to < 69, and 35 U/L for males and 32 U/L for females aged ≥ 69.

  5. Percentage of Participants With HBeAg Loss at Weeks 48, 96, 144, 192, and 240

    Time frame: Baseline; Weeks 48, 96, 144, 192, and 240

    The percentage of participants who were HBeAg positive at baseline and who had HBeAg Loss at the given time point was summarized. Loss of HBeAg was defined as change of detectable HBeAg from positive to negative.

  6. Percentage of Participants With Seroconversion to Antibody Against HBeAg (Anti-HBe) at Weeks 48, 96, 144, 192, and 240

    Time frame: Baseline; Weeks 48, 96, 144, 192, and 240

    The percentage of participants who were HBeAg positive at baseline and who had seroconversion to anti-HBe at the given time point was summarized. Seroconversion to anti-HBe was defined as change of detectable antibody to HBeAg from negative to positive.

  7. Percentage of Participants With HBV Surface Antigen (HBsAg) Loss at Weeks 48, 96, 144, 192, and 240

    Time frame: Baseline; Weeks 48, 96, 144, 192, and 240

    The percentage of participants with HBsAg Loss at the given time point was summarized. Loss of HBsAg was defined as change of detectable HBsAg from positive to negative.

  8. Percentage of Participants With Seroconversion to Antibody Against HBV Surface Antigen (Anti-HBs) at Weeks 48, 96, 144, 192, and 240

    Time frame: Baseline; Weeks 48, 96, 144, 192, and 240

    The percentage of participants with seroconversion to anti-HBs at the given time point was summarized. Seroconversion to anti-HBs was defined as change of detectable antibody to HBsAg from negative to positive.

  9. Percentage of Participants With Virologic Breakthrough at Weeks 48, 96, 144, 192, and 240

    Time frame: Baseline; Weeks 48, 96, 144, 192, and 240

    The percentage of participants with virologic breakthrough at the given time point was summarized. Virologic breakthrough was defined as having two consecutive 1.0 log10 or greater increases in serum HBV DNA from on-treatment nadir, or two consecutive HBV DNA values ≥ 400 copies/mL after being < 400 copies/mL.

  10. Percent Change From Baseline in Bone Mineral Density (BMD) of the Spine at Weeks 24, 48, 72, 96, 144, 192, and 240

    Time frame: Baseline; Weeks 24, 48, 72, 96, 144, 192, and 240

    BMD is calculated as grams per cubic centimeter (g/cm^2); the mean (SD) percentage change is presented.

  11. Percent Change From Baseline in BMD of the Hip at Weeks 24, 48, 72, 96, 144, 192, and 240

    Time frame: Baseline; Weeks 24, 48, 72, 96, 144, 192, and 240

    BMD is calculated as g/cm^2; the mean (SD) percentage change is presented.

  12. Development of Drug-resistant Mutations (DRMs)

    Time frame: Baseline to Week 240

    The development of DRMs was summarized, either as development of new DRMs or enrichment of existing DRMs.

Sponsors and collaborators

Lead sponsor

Gilead Sciences

Industry

Registry information

Official study title

A Phase 3b, Randomized, Double-Blind, Double-Dummy Study Evaluating the Antiviral Efficacy, Safety, and Tolerability of Tenofovir Disoproxil Fumarate (DF) Monotherapy Versus Emtricitabine Plus Tenofovir DF Fixed-Dose Combination Therapy in Subjects With Chronic Hepatitis B Who Are Resistant to Lamivudine

Important dates

Study start
2008
Primary completion
2011
Study completion
2015
First posted
Aug 19, 2008
Registry last updated
Mar 11, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.